Bristol Myers' manufacturing shutdown means lower-than-expected Q3 sales for Abecma
Bristol Myers Squibb and 2seventy bio said this week that a manufacturing shutdown will translate to lower-than-expected sales for their CAR-T cell therapy Abecma in the third quarter.
“We think Q3 sales will be roughly in line with Q2, but will return to growth again as we get into Q4,” Bristol Myers COO and CEO-designate Chris Boerner said Monday at Morgan Stanley’s healthcare conference in New York.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.